104 related articles for article (PubMed ID: 15940337)
21. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
22. [No influence of imatinib on type 2 diabetes].
Chodorowski Z; Sein Anand J; Hellmann A; Prejzner W
Przegl Lek; 2007; 64(4-5):370-1. PubMed ID: 17724918
[TBL] [Abstract][Full Text] [Related]
23. Effect of insulin-glucose infusion on mortality following acute myocardial infarction in patients with diabetes: the diabetes and insulin-glucose infusion in acute myocardial infarction studies.
Malmberg K; Rydén L
Semin Thorac Cardiovasc Surg; 2006; 18(4):326-9. PubMed ID: 17395029
[TBL] [Abstract][Full Text] [Related]
24. Redefining insulin therapy in type 2 diabetes mellitus.
Rosenstock J
Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
[TBL] [Abstract][Full Text] [Related]
25. [Insulin treatment in type 2 diabetes].
Birkeland KI
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):919-20. PubMed ID: 16554885
[No Abstract] [Full Text] [Related]
26. A 48-year-old man with uncontrolled diabetes.
Hu M; Isaacson JH
Cleve Clin J Med; 2009 Jul; 76(7):413-6. PubMed ID: 19570974
[No Abstract] [Full Text] [Related]
27. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
28. [Better blood glucose control. Extending metformin dosage].
MMW Fortschr Med; 2001 Sep; 143(38):59. PubMed ID: 11601099
[No Abstract] [Full Text] [Related]
29. [Glucides in the nutrition of diabetics].
Maillard C
Servir; 2002; 50(5):244-6. PubMed ID: 12494529
[No Abstract] [Full Text] [Related]
30. Optimizing management of type 2 diabetes in hospitalized patients who are not critically ill.
Vigersky RA
Diabetes Technol Ther; 2005 Oct; 7(5):831-3. PubMed ID: 16241893
[No Abstract] [Full Text] [Related]
31. Continuous Glucose Monitoring Use in Hospitalized Patients.
Dungan KM
Diabetes Technol Ther; 2015 Sep; 17(9):600-2. PubMed ID: 25978126
[No Abstract] [Full Text] [Related]
32. [Selection and dosing of insulin preparations].
Kajinuma H
Nihon Rinsho; 1997 Nov; 55 Suppl():238-42. PubMed ID: 9434474
[No Abstract] [Full Text] [Related]
33. Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus.
Spigset O; Mjörndal T
J Intern Med; 1999 Oct; 246(4):419-22. PubMed ID: 10583713
[No Abstract] [Full Text] [Related]
34. [Insulin resistance in type-2 diabetes].
Hübinger A
Dtsch Med Wochenschr; 1992 Mar; 117(11):437-8. PubMed ID: 1544347
[No Abstract] [Full Text] [Related]
35. [Give them a pill?].
Beck-Nielsen H
Ugeskr Laeger; 2000 Jun; 162(23):3304. PubMed ID: 10895594
[No Abstract] [Full Text] [Related]
36. Comment on: Harrison et al. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412.
Aizawa T; Yamauchi K
Diabetes Care; 2013 Jan; 36(1):e16. PubMed ID: 23264299
[No Abstract] [Full Text] [Related]
37. Metformin as firstline treatment for type 2 diabetes: are we sure?
Boussageon R; Gueyffier F; Cornu C
BMJ; 2016 Jan; 352():h6748. PubMed ID: 26747716
[TBL] [Abstract][Full Text] [Related]
38. Response to Comment on: Harrison et al. β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412.
Harrison LB; Raskin P; Lingvay I
Diabetes Care; 2013 Jan; 36(1):e17. PubMed ID: 23264300
[No Abstract] [Full Text] [Related]
39. Cases: "safety" technology: a hidden cause of diabetic ketoacidosis.
Yu CH
CMAJ; 2012 Mar; 184(5):557-8. PubMed ID: 22371509
[No Abstract] [Full Text] [Related]
40. Real-world assessment of glycemic control after V-Go® initiation in an endocrine practice in the southeastern United States.
Johns BR; Jones TC; Sink JH; Cooke CE
J Diabetes Sci Technol; 2014 Sep; 8(5):1060-1. PubMed ID: 24876455
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
